Welcome to our dedicated page for Gh Research Plc SEC filings (Ticker: GHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can bury crucial details—especially when they span hundreds of pages of pharmacology jargon and trial protocols. GH Research Plc’s disclosures are no exception; cash runway assumptions, Phase 2 trial readouts, and mebufotenin safety data are scattered across multiple forms. Locating GH Research insider trading Form 4 transactions or the latest pipeline update shouldn’t require a PhD in regulatory paperwork.
Stock Titan’s AI decodes every document the moment it hits EDGAR. Need the GH Research quarterly earnings report 10-Q filing? Our platform highlights R&D spend, remaining cash, and trial costs in plain language. Looking for GH Research Form 4 insider transactions real-time? Instant alerts point to buying or selling trends that may signal confidence in upcoming data. We also offer single-click access to:
- GH Research annual report 10-K simplified—risk factors, patent status, and cash projections clarified
- GH Research proxy statement executive compensation—see how leadership incentives align with clinical milestones
- GH Research 8-K material events explained—rapid breakdowns of trial results or FDA feedback
Whether you’re understanding GH Research SEC documents with AI for the first time or need deeper GH Research earnings report filing analysis, our summaries, red-flag alerts, and keyword search cut hours from your workflow. Monitor GH Research executive stock transactions Form 4, follow cash burn across quarters, and see which disclosures move the share price—all in one place, all explained simply.
GH Research PLC reports that it has been accepted to the Promising Targets Oral Session at the 64th American College of Neuropsychopharmacology annual meeting. The company will present results from its GH001-TRD-201 clinical trial, which focuses on treatment‑resistant depression, during this scientific congress. The meeting is scheduled for January 12–15, 2026 in Nassau, Bahamas, and the presentation will be delivered by Prof Michael E. Thase. An abstract of the presentation content is provided as an exhibit to this report, giving additional detail on the trial results to the scientific and investment community.
GH Research PLC (GHRS) reported that it will participate in a fireside chat and hold one-on-one investor meetings during the Stifel 2025 Healthcare Conference in New York. The conference is scheduled for November 11–13, 2025.
This is a routine investor-relations update that signals engagement with the investment community through a formal conference appearance and direct meetings.
GH Research PLC furnished a Form 6-K announcing third quarter 2025 financial results, business updates, and an updated investor presentation. The company made available a press release and presentation dated November 6, 2025.
The submission includes unaudited interim financial statements and MD&A, plus Inline XBRL files. The report (excluding Exhibits 99.3 and 99.4) is incorporated by reference into the company’s Form S-8 registrations and its Form F-3 shelf.
GH Research PLC reported that posters from its GH001-TRD-201 clinical program were accepted for presentation at the 64th American College of Neuropsychopharmacology annual meeting, scheduled for January 12–15, 2026 in Nassau, Bahamas. The submission set includes three abstracts: suicidal ideation and behavior in treatment-resistant depression (Ex. 99.1; presenter Sanjay J. Mathew), rapid antidepressant effects of inhaled GH001 in treatment-resistant depression from a Phase 2b randomized trial with 6‑month follow-up (Ex. 99.2; presenter Lisa Harding), and efficacy and safety of inhaled mebufotenin (GH001) in Bipolar II depression from a Phase 2a trial (Ex. 99.3; presenter Andreas Reif).
GH Research PLC filed a Form 6-K announcing the presentation of data from its GH001-TRD-201 clinical trial at the 38th European College of Neuropsychopharmacology annual meeting in Amsterdam. The Congress is scheduled for October 11–14, 2025.
The presentation, delivered by Prof. Wiesław J. Cubała on October 13, 2025 during the Novel Therapies Symposium, is provided as Exhibit 99.1. This update is informational and centers on the public disclosure of clinical data via a scientific conference presentation.
RA Capital and related persons report a 12.4% stake in GH Research PLC as of June 30, 2025. The filing shows aggregate ownership of 7,676,697 Ordinary Shares out of 62,028,145 outstanding, based on the issuer's February 15, 2025 filing. The RA Capital Healthcare Fund directly holds 7,485,080 shares (12.1%) and RA Capital Nexus Fund II holds 191,617 shares. Reported holdings reflect shared voting and shared dispositive power only; sole voting and dispositive power are zero. The filing states RA Capital serves as investment adviser and has sole power to vote and dispose of the funds’ reported shares, while the funds disclaim beneficial ownership for purposes of Section 13(d) because they delegated those powers and may not revoke that delegation on less than 61 days’ notice.
FAQ
What is the current stock price of Gh Research Plc (GHRS)?
What is the market cap of Gh Research Plc (GHRS)?
